Shares of Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) rose 3.4% on Monday . The stock traded as high as C$2.60 and last traded at C$2.40. Approximately 6,051 shares changed hands during mid-day trading, a decline of 18% from the average daily volume of 7,410 shares. The stock had previously closed at C$2.32.
Eupraxia Pharmaceuticals Price Performance
The firm has a 50-day simple moving average of C$2.60 and a two-hundred day simple moving average of C$2.70.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Featured Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- Most active stocks: Dollar volume vs share volume
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
